EXHIBIT 10_1
Termination of License Agreement
This Early Termination of Vivarium Agreement (“Termination Agreement”) is dated September 9, 2022 (“Execution Date”) and is entered into by and between Cue Biopharma, Inc., (“Licensee”) and MIL 21E, LLC (“Licensor”).
WHEREAS, Licensor and Licensee are parties to a certain Vivarium Agreement dated September 20, 2018, as amended (the “Vivarium Agreement”);
WHEREAS, Licensee warrants and represents that, to the best of its knowledge, Licensor has fulfilled its obligations under the Vivarium Agreement and is not in default of any covenants or obligations contained in the Vivarium Agreement;
WHEREAS, Licensor and Licensee desire to terminate the Vivarium Agreement on the terms and conditions set forth herein; and
WHEREAS, capitalized terms used herein but not defined herein shall have the meaning ascribed to them in the Vivarium Agreement.
For good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, accepted and agreed to, Licensor and Licensee agree as follows:
EXHIBIT 10_1
fails to fully remove itself and all of its personal property from the Vivarium Premises as of the Termination Date, Licensee shall be liable for any consequential damages that arise directly therefrom, including but not limited to those arising out of such new licensee terminating its agreement with Licensor.
IN WITNESS WHEREOF, the parties hereto have executed this Termination Agreement as of the Execution Date.
LICENSOR LICENSEE
/s/ Brian Taylor |
| /s/ Kerri-Ann Millar |
Name: Brian Taylor |
| Name: Kerri-Ann Millar |
Title: Head of Biopharma Solutions |
| Title: Chief Financial Officer |
|
| (Principal Financial Officer and Principal Accounting Officer) |